EUVIMEDEUVIMED entdecken
Open Access

Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales

Gregory Weston iD, Abhigya Giri, Lauren Komarow, Lizhao Ge, Keri R Baum, Erin Abbenante, Jason C Gallagher iD, Jesse T Jacob iD, Keith S Kaye iD, Angela C Kim, W Charles Huskins, Marcus Zervos iD und 4 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae186 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Gregory Weston und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA. Hauptthemen laut MEDLINE: Ertapenem, Anti-Bacterial Agents, Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NIAID, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Use of anti-carbapenem-resistant Enterobacterales (anti-CRE) agents such as ceftazidime/avibactam has been associated with improved clinical outcome in cohorts that primarily include patients infected with CRE that are resistant to meropenem (MCRE).

Objectives

To clarify whether patients with CRE resistant to ertapenem but susceptible to meropenem (ertapenem-only-resistant Enterobacterales; EORE) benefit from therapy with anti-CRE agents.

Methods

Patients treated for CRE infection in hospitals in the USA between 2016 and 2019 and enrolled in the CRACKLE-2 study were included. The primary outcome was the desirability of outcome ranking (DOOR) assessed at 30 days after index cultures.

Results

The EORE group included 213 patients and the MCRE group included 643. The demographics were similar between the groups except for the patients’ race and origin before admission. The MCRE group received anti-CRE agents for definitive therapy significantly more frequently compared with the EORE group (30% versus 5% for ceftazidime/avibactam). We did not observe a significant difference between the groups in the adjusted DOOR probability of a more desirable outcome for a randomly selected patient in the EORE group compared with the MCRE group (52.5%; 95% CI, 48.3%–56.7%). The MCRE group had a similar proportion of patients who died at 30 days (26% versus 21%) and who were discharged to home (29% versus 40%), compared with the EORE group.

Conclusions

Patients with clinical EORE infection rarely received anti-CRE agents, but attained similar outcomes compared with patients with MCRE infection. The findings support current IDSA treatment guidance for meropenem- or imipenem-based therapy for treatment of EORE infections.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErtapenemAnti-Bacterial AgentsEnterobacteriaceae InfectionsCarbapenem-Resistant EnterobacteriaceaeCeftazidimeHumansMaleFemaleMiddle AgedAgedTreatment OutcomeMeropenemDrug CombinationsAzabicyclo CompoundsMicrobial Sensitivity TestsDrug Resistance, Multiple, BacterialAdultEnterobacteriaceae

Substanzen

ErtapenemAnti-Bacterial AgentsCeftazidimeavibactam, ceftazidime drug combinationMeropenemDrug CombinationsAzabicyclo Compounds

Autor:innen und Institutionen

  • Division of Infectious Diseases, Department of Medicine, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, USA.
  • The Biostatistics Center, George Washington University, Rockville, MD, USA.
  • Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC, USA.
  • Department of Pharmacy Practice, Temple University School of Pharmacy, Philadelphia, PA, USA.
  • Division of Infectious Diseases, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.
  • Division of Allergy, Immunology and Infectious Diseases, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, USA.

ORCID-Profile: Gregory Weston, Jason C Gallagher, Jesse T Jacob, Keith S Kaye, Marcus Zervos, Robin Patel, David Van Duin, Yohei Doi

Förderung

  • NIAID NIH HHS
  • NIAID
  • NIH HHS
  • NIH

Zitieren

APA

Weston, G., Giri, A., Komarow, L., Ge, L., Baum, K. R., Abbenante, E., Gallagher, J. C., Jacob, J. T., Kaye, K. S., Kim, A. C., Huskins, W. C., Zervos, M., Herc, E., Patel, R., Van Duin, D., & Doi, Y. (2024). Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae186

Vancouver

Weston G, Giri A, Komarow L, Ge L, Baum KR, Abbenante E, et al. Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae186

BibTeX
@article{Weston2024,
  author = {Weston, Gregory and Giri, Abhigya and Komarow, Lauren and Ge, Lizhao and Baum, Keri R and Abbenante, Erin and Gallagher, Jason C and Jacob, Jesse T and Kaye, Keith S and Kim, Angela C and Huskins, W Charles and Zervos, Marcus and Herc, Erica and Patel, Robin and Van Duin, David and Doi, Yohei},
  title = {Clinical outcomes in patients infected with ertapenem-only-resistant Enterobacterales versus multi-carbapenem-resistant Enterobacterales},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae186}
}
Kostenlos starten →